Demin M V, Tikhomirov D S, Biderman B V, Drokov M Yu, Sudarikov A B, Tupoleva T A, Filatov F P
FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia.
FSBRI «I.I. Mechnikov Research Institute of Vaccines and Sera»; FSBI «National Research Centre for Epidemiology and Microbiology named after honorary academician N.F. Gamaleya» of the Ministry of Health of Russia.
Vopr Virusol. 2022 Mar 15;67(1):37-47. doi: 10.36233/0507-4088-90.
Infection caused by cytomegalovirus (CMV) is a serious problem for patients with weakened immunity, including patients with hematopoietic depression. The cases of complications associated with cytomegalovirus require antiviral therapy. However, during the natural mutation process, especially with prolonged use of drugs in suboptimal doses, CMV strains resistant to the action of antiviral drugs (such as ganciclovir, valganciclovir) may occur. Hypothetically, the emergence of resistance in the virus may cause a more aggressive course of infection, the ineffectiveness of antiviral therapy and, as a result, an increase in the number of deaths. In this regard, timely detection of mutations that can potentially lead to the resistance of the virus to antiviral drugs during hematopoietic stem cell transplantation (HSCT), as well as during organ and tissue transplantation, may be important when making a therapeutic decision. We describe three clinical cases for which the dynamics of the appearance of a mutant strain of CMV by the UL97 gene, which correlates with the viral load and clinical picture, is analyzed.The aim of the study was to determine the timing of the occurrence of mutations in CMV phosphotransferase UL97 gene associated with resistance to antiviral drugs in patients with hemoblastoses after allogeneic hematopoietic stem cell (allo-HSCs) transplantation.
The study included 48 samples of CMV DNA isolated from the peripheral blood of three allo-HSCs recipients with CMV infection who were treated in the clinics of the FSBI «National Medical Research Center for Hematology» of the Ministry of Health of Russia with oncohematological diseases during 2015-2017. Patients received conditional codes (PR, PD, and FS). Mutations associated with antiviral therapy (AVT) resistance were identified in all patients. Sanger sequencing was used for mutation detection. The obtained DNA sequences were analyzed using Nucleotide BLAST and Genome compiler software. Mutations were searched in MRA mutation resistance analyzer software. The nucleotide sequences were compared with the UL97 reference sequence of the Merlin CMV strain using this software environment.
For all patients in whom the virus strains containing C592G (PR), C607F (PD) and C603W (FS) mutations were detected, the timing of the mutation occurrence was determined at days 187, 124 and 1184, respectively. The emergence of mutations with a high resistance factor was shown to be accompanied by an increase in viral load (VL), the appearance of a clinical picture characteristic of CMV infection and a lack of an adequate response to therapy with ganciclovir and its derivatives.
Using these results, it is proposed to develop the test system based on random polymerase chain reaction (rPCR) to detect mutations in the most frequently encountered codons: M460I/V, C592G, A591V, A594T/V, L595F/S, C603W. Given that the data on the prevalence of these mutations were obtained from foreign sources, it is advisable to conduct similar studies on the frequency of mutations in the UL97 gene among the population of the Russian Federation in order to improve the quality and accuracy of test systems.
巨细胞病毒(CMV)感染对于免疫功能较弱的患者,包括造血功能低下的患者来说是一个严重问题。与巨细胞病毒相关的并发症病例需要抗病毒治疗。然而,在自然突变过程中,特别是在以次优剂量长期使用药物时,可能会出现对抗病毒药物(如更昔洛韦、缬更昔洛韦)产生耐药性的CMV毒株。从理论上讲,病毒耐药性的出现可能导致感染过程更具侵袭性、抗病毒治疗无效,进而导致死亡人数增加。因此,在造血干细胞移植(HSCT)以及器官和组织移植过程中,及时检测可能导致病毒对抗病毒药物产生耐药性的突变,对于做出治疗决策可能很重要。我们描述了三例临床病例,分析了与病毒载量和临床表现相关的CMV UL97基因突变株出现的动态情况。本研究的目的是确定异基因造血干细胞(allo-HSCs)移植后血液病患者中与抗病毒药物耐药相关的CMV磷酸转移酶UL97基因突变发生的时间。
本研究纳入了2015 - 2017年期间在俄罗斯卫生部联邦国家预算机构“国家血液学医学研究中心”临床治疗的3例allo-HSCs移植且感染CMV的血液病患者外周血中分离出的48份CMV DNA样本。患者被赋予条件代码(PR、PD和FS)。在所有患者中鉴定出与抗病毒治疗(AVT)耐药相关的突变。采用桑格测序法进行突变检测。使用核苷酸BLAST和基因组编译器软件对获得的DNA序列进行分析。在MRA突变耐药分析软件中搜索突变。在该软件环境下将核苷酸序列与Merlin CMV毒株的UL97参考序列进行比较。
对于所有检测到含有C592G(PR)、C607F(PD)和C603W(FS)突变的病毒株的患者,分别确定突变发生时间为第187天、第124天和第1184天。结果表明,具有高耐药因子的突变出现伴随着病毒载量(VL)增加、出现CMV感染的典型临床表现以及对更昔洛韦及其衍生物治疗缺乏充分反应。
基于这些结果,建议开发基于随机聚合酶链反应(rPCR)的检测系统,以检测最常见密码子的突变:M460I/V、C592G、A591V、A594T/V、L595F/S、C603W。鉴于这些突变流行率的数据来自国外,为提高检测系统的质量和准确性,建议对俄罗斯联邦人群中UL97基因突变频率进行类似研究。